Evaluation Data Shows New Fingertip-Sweat Drug Screening Device can Offer Coroners Early Intelligence on Cause of Death

Successful proof of concept with the Sheffield Coroner leads to wider customer trial

11 Oct 2015
Lois Manton-O'Byrne
Executive Editor

Discussions to extend the pilot of a new mobile drug screening technology pioneered by British company Intelligent Fingerprinting to nine coroners’ areas are underway following presentation of evaluation data to the recent Coroner’s Society of England and Wales Annual Conference. The trial is validating a new non-invasive drug screening technique that could help coroners prioritize when costly post-mortems are needed and enable earlier release of the deceased for burial.

Last year 223,841 deaths were reported to coroners in England and Wales.1 Of these, 40% required a full post mortem examination to assist in determining the cause of death.1 A post mortem often includes toxicology tests to determine the presence of any drugs that might provide an insight into the cause of death. Intelligent Fingerprinting’s drug screening device collects and analyses sweat from a person’s fingertip to provide information on recent drug use, with results in under ten minutes. It could potentially be used within mortuaries to provide early intelligence of drug use .

The Coroner’s Society Conference was shown data from a pilot being conducted by Intelligent Fingerprinting and the Sheffield Legal-Medico Centre. This trial, funded by the government’s innovation agency Innovate UK, is testing potential use of the Intelligent Fingerprinting drug screening device by coroners and mortuary staff to gather early intelligence about cause of death.

Mr Christopher Dorries, HM Coroner South Yorkshire West Area has said: “It has been fascinating to watch this technology being developed stage by stage. Although we are at an early stage of comparing results with the nearly finished product, the testing so far has suggested that this will be a really useful tool for bed-side toxicology indication, albeit not intended to be evidential. It should alert us to the cases that need to be subject to full toxicology, and in some cases, may obviate the need for any toxicology tests at all.”

With the relatives’ consent, 180 fingertip sweat samples collected from the Sheffield mortuary ‑ representing a wide range of categories of death and preservation of bodies ‑ were tested in Intelligent Fingerprinting’s laboratory for the presence of opiates. A correlation of over 90% was achieved in samples analyzed using Intelligent Fingerprinting’s technology compared with post-mortem toxicology results. Samples are now being tested in real time in the mortuary using the company’s portable drug screening device and the first results show a similar correlation to conventional post-mortem toxicology results for opiates and cocaine.

Speaking at the Coroner’s Society Conference where the preliminary results were presented, Dr Paul Yates from Intelligent Fingerprinting said: “This new non-invasive technology has the potential to provide early intelligence about drug use to help determine the likely cause of death and allow coroners to prioritize where a full post-mortem and laboratory toxicology tests are required, thereby saving costs. The device could also quickly reveal the presence of drugs in cases which may otherwise have been overlooked as unsuspicious.”

“We are very pleased by the enthusiasm shown by other coroners offering to help us build our data set by taking part in a wider trial of our device,” added Dr Yates.

Links

Tags